文拉法辛与米氮平治疗老年抑郁症的临床研究

摘要

目的：比较文拉法辛与米氮平治疗老年期抑郁症的疗效和安全性。方法：将103例60岁以上的抑郁症患者随机分为治疗组（文拉法辛组，53例）、对照组（米氮平组，50例），疗程均为8周。分别于治疗前及治疗后第1、2、4、8周末使用汉密尔顿抑郁量表（HAMD）17项、生活质量综合评定问卷、副反应量表（TESS）评价临床疗效、生活质量和不良反应。结果：两组均完成治疗，治疗组和对照组有效率分别为92.5％和90.0％，两组患者疗效差异无统计学意义（P＞0.05），两组患者均未出现严重的不良反应。结论：米氮平与文拉法辛用于治疗老年抑郁症疗效与安全性相当，均可作为治疗抑郁症的一线药物。%OBJECTIVE:To evaluate the clinical efficacy and safety of venlafaxine vs. mirtazapine in the treatment of depres-sion in old age. METHODS:A total of 103 patients aged above 60 years with depression were randomly assigned to either treat-ment group receiving venlafaxine (53 cases) or control group receiving mirtazapine (50 cases) for treatment of 8 weeks. Before treatment and at 0,1,2,4 and 8 weeks of treatment,the clinical efficacy,quality of life and adverse effects were evaluated using Hamilton depression scale(HAMD)(17 items),Generic Quality of life Inventory(GQOLI)and side effects scale(TESS)respec-tively. RESULTS:All patients completed the treatment;the effective rate in the treatment group vs. control group was 92.5% vs. 90.0%(P>0.05);serious adverse reactions were noted in none of groups. CONCLUSIONS:Mirtazapine is as effective and safe as venlafaxine for depression in old age thus both can be used as the first-line drug for the treatment of depression.